Pacira BioSciences, Inc.PCRXNASDAQ
Loading
PCRX Revenue Growth (YoY Quarterly)•+5.14%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+5.14%
-1.4pp
-3.47%
-15.4pp
-51.52%
-51.5pp
-87.08%
-87.1pp
-89.79%
-89.8pp
-89.00%
-89.0pp
-88.79%
-88.8pp
-7.97%
-3.4pp
-12.35%
-8.7pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +3.32% | +1.08% | +1.73% | +6.49% | +5.14% |
| Gross Profit Growth | +10.34% | +12.46% | +4.84% | +11.97% | -3.47% |
| EBITDA Growth | -7.84% | -3.15% | -50.07% | +0.00% | -51.52% |
| Operating Income Growth | -25.52% | -84.94% | -69.90% | +0.00% | -87.08% |
| Net Income Growth | -35.50% | -46.41% | -125.66% | +0.00% | -89.79% |
| EPS Growth | -34.65% | -47.37% | -126.83% | +0.00% | -89.00% |
| EPS Diluted Growth | -28.83% | -47.37% | -128.21% | +0.00% | -88.79% |
| Weighted Average Shares Growth | -0.57% | -0.48% | -1.55% | -4.54% | -7.97% |
| Weighted Average Shares Diluted Growth | -5.82% | -10.86% | -10.05% | -3.63% | -12.35% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -30.37% | -27.78% | -77.44% | +12.82% | +31.86% |
| Free Cash Flow Growth | -32.26% | -41.83% | -81.96% | +14.32% | +40.17% |
| Receivables Growth | +7.34% | +3.06% | +9.15% | +14.72% | +9.50% |
| Inventory Growth | +20.06% | +38.20% | +43.24% | +40.96% | +22.02% |
| Asset Growth | -1.33% | +0.21% | -6.65% | -14.73% | -18.58% |
| Book Value per Share Growth | -10.03% | -10.06% | -12.46% | +1.63% | -3.24% |
| Debt Growth | +9.01% | +9.40% | -2.65% | -34.00% | -28.88% |
| R&D Expense Growth | +22.78% | +38.95% | +38.66% | +35.92% | +56.73% |
| SG&A Expenses Growth | +20.99% | +20.48% | +30.02% | +23.49% | +27.63% |
1 / 4